Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7474MR)

This product GTTS-WQ7474MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets TNFRSF4 gene. The antibody can be applied in Atopic dermatitis (AD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_003327.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7293
UniProt ID P43489
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ7474MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1607MR IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ACE-536
GTTS-WQ210MR IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 13C5.5
GTTS-WQ7863MR IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GSK-2398852
GTTS-WQ8290MR IVTScrip™ mRNA-Anti-GHR, HM10560A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA HM10560A
GTTS-WQ2131MR IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ALD-403
GTTS-WQ12711MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OMP-305B83
GTTS-WQ11674MR IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MHAA4549A
GTTS-WQ11787MR IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MK-3222
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW